4 completed, 3 unknown, 2 recruiting, 2 suspended. 9 Phase 1, 5 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Suspended 2, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 5 | Recruiting 2, Completed 1, Not yet recruiting 1, Unknown 1 |
| Early Phase 1 | 1 | Unknown 1 |
Follow Advanced Refractory Solid Tumors: new trials by email Literature Review of Advanced Refractory Solid Tumors trials Research Report on Advanced Refractory Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive Becotatug Vedotin, Pucotenlimab - Advanced Refractory Solid Tumors, EGFR Gene Overexpression | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 32 | 2026-08-01 | 2026-07-17 |
| Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors Hypofractionated radiotherapy, PD-L1 inhibitor, GM-CSF - Advanced Refractory Solid Tumors | Phase 2 | Not yet recruiting | Second Affiliated Hospital of Soochow University | 40 | 2025-12-27 | 2026-01-08 |
| Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors CB-03-10 - Advanced Refractory Solid Tumors, Subjects Considered Likely to Respond to CB-03-10 | Early Phase 1 | Unknown | Cosmo Technologies Ltd | 90 | 2022-06-14 | 2024-02-07 |
| Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0) Hypofractionated radiotherapy, PD-1 inhibitor, GM-CSF - Advanced Refractory Solid Tumors | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 66 | 2021-05-30 | 2022-08-09 |
| Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) Talazoparib, Selinexor - Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers | Phase 1 / Phase 2 | Recruiting | National University Hospital, Singapore | 63 | 2021-03-01 | 2025-07-25 |
| Safety and Tolerability Study for T-1101 (Tosylate) Capsules to Treat Advanced Refractory Solid Tumors T-1101 (Tosylate) - Advanced Refractory Solid Tumors | Phase 1 | Completed | Taivex Therapeutics Corporation | 24 | 2021-01-07 | 2026-07-08 |
| A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors CS1001, Regorafenib - Advanced Refractory Solid Tumors | Phase 1 / Phase 2 | Completed | CStone Pharmaceuticals | 19 | 2019-12-13 | 2022-05-06 |
| Clinical Study of HEC68498 in Patients With Advanced Refractory Solid Tumors HEC68498 - Advanced Refractory Solid Tumors | Phase 1 | Completed | Sunshine Lake Pharma Co., Ltd. | 12 | 2019-02-27 | 2022-08-12 |
| Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors T-1101 (Tosylate) - Advanced Refractory Solid Tumors | Phase 1 | Terminated | Taivex Therapeutics Corporation | 21 | 2017-09-14 | 2022-11-18 |
| An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors T-1101 (Tosylate) - Advanced Refractory Solid Tumors | Phase 1 | Completed | Taivex Therapeutics Corporation | 3 | 2017-09-14 | 2022-11-18 |
| NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors NOV120401 - Advanced Refractory Solid Tumors | Phase 1 | Unknown | National OncoVenture | 30 | 2014-12-01 | 2015-08-14 |
| Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors PL225B - Advanced Refractory Solid Tumors | Phase 1 | Suspended | Piramal Enterprises Limited | 70 | 2012-12-01 | 2014-09-29 |
| Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors P7170 - Advanced Refractory Solid Tumors | Phase 1 | Suspended | Piramal Enterprises Limited | 60 | 2012-09-01 | 2014-09-29 |
Breast Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Breast Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Granulocyte-Macrophage Colony-Stimulating Factor (2) · Immune Checkpoint Inhibitors (2) · Radiation Dose Hypofractionation (2) · Interleukin-2 (1) · N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide (1) · P7170 compound (1) · envafolimab (1) · regorafenib (1) · selinexor (1) · talazoparib (1)
Taivex Therapeutics Corporation (3) · Piramal Enterprises Limited (2) · Second Affiliated Hospital of Soochow University (2) · CStone Pharmaceuticals (1) · Cosmo Technologies Ltd (1) · National OncoVenture (1) · National University Hospital, Singapore (1) · Sunshine Lake Pharma Co., Ltd. (1) · Tianjin Medical University Second Hospital (1)
China (4) · Taiwan (3) · United States (3) · India (2) · Australia (1) · Singapore (1) · South Korea (1)
Anthony El-Khoueiry, MD (1) · Dr Anthony El-Khoueiry, MD (1) · Haitao Wang, Ph.D. (1) · Jung Yong Kim, MD (1) · Liyuan Zhang, Dr (1) · Min Chae Kim, Pharmacist (1) · Soo Chin Lee (1)
PMID 12538758, PMID 14996737, PMID 21563193, PMID 21868756, PMID 21969517, PMID 22223138, PMID 23341367, PMID 24131140, PMID 24315100, PMID 24615402, PMID 25535299, PMID 25595907, PMID 26115975, PMID 26483423, PMID 26566796, PMID 27300548, PMID 28293120, PMID 28428441, PMID 29158269, PMID 29373071, PMID 30345906, PMID 30689707, PMID 7082756